MedTrace Logo

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-08-11

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Conditions

  • Mild to Moderate Alzheimer's Disease

Interventions

DRUG

CT1812

Active Study Drug

DRUG

Placebo

Non-active study drug

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Anthony Caggiano, MD · Cognition Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2024-05-29
Completion
2024-05-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Czechia
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03507790 on ClinicalTrials.gov